A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 08 Oct 2019 Status changed from suspended to active, no longer recruiting.
- 22 Apr 2019 Status changed from recruiting to suspended.
- 20 Mar 2019 Planned number of patients changed from 48 to 66.